30-Day Open-Label Observational Findings

Participant-Reported Changes in Symptom Frequency, Severity, and Daily Well-Being

Study Overview

Electron Colloidal conducted a 30-day open-label customer observation involving 40 adults between the ages of 40 and 65 to document their experiences while using Colloidal Magnesium. The observation focused on participant-reported changes in the frequency, intensity, and severity of heart skips, palpitations, flutters, and episodes of rapid heartbeat. Feedback also included experiences from individuals who reported a history of premature ventricular contractions (PVCs), supraventricular tachycardia (SVT), and atrial fibrillation (AFib). Participants described changes in their symptoms, their ability to perform daily activities, and their overall sense of well-being. A subsequent 90-day follow-up collected additional customer feedback regarding longer-term experiences.

Research Methodology & Data Transparency

We measured how quickly participants experienced symptom relief, tracking reported reductions in symptom frequency, intensity, or both throughout the 30-day observational study. Percentages reflect the proportion of participants who reported improvement by each time point.

Summary of Reported Findings

0% 17.5%

Week 1 | Initial Symptom Response

Participants reported early reductions in the frequency and intensity of heart skips and palpitations, with some noticing substantial changes within the first seven days.

0% 85%

Weeks 2–3 | Continued Symptom Improvement

Participants reported continued improvement in symptom frequency and intensity, with many describing milder episodes that became less disruptive to their daily activities.

0% 95%

Week 4 | Overall Symptom Improvement

Participants reportedly experienced minimal or no noticeable heart skips and palpitations by day 30, including some with a reported history of cardiac arrhythmias.

Selected participant reports

Reported Daily Usage by Symptom Group

Selected participant-reported daily usage patterns during the observation period.

PAC

3 x1ml doses daily

PVCs & PACs — Some participants

2 x1ml doses daily

Tachycardia

3 x1ml doses daily

AFIb

4 x1ml doses daily

Blood Pressure

3 x1ml doses daily

Data reflects selected participant-reported daily usage patterns during the 30-day open-label observational period, including individuals reporting PVCs, PACs, tachycardia, AFib, and blood pressure concerns. Each dose represents 1 mL of Colloidal Magnesium.

Progress Beyond 30 Days

Heart Rhythm

Some reported as few as 1–2 noticeable episodes per month

Daily Endurance

Participants described greater comfort during everyday activities.

Sleep Quality

Some described fewer nighttime interruptions

Longer-Term Progress

Participants described maintaining improvements beyond day 30.

90-Day Follow-Up: Longer-Term Participant Experiences

Following the initial 30-day observational period, participants reported continued improvements in overall well-being. Some with a history of heart irregularities experienced fewer episodes per month, while others described greater endurance, improved sleep quality, and fewer nighttime interruptions.

Follow-Up Disclosure

Findings reflect voluntary, participant-reported experiences during the 90-day follow-up period. Some participants reported improvements in ECG and Holter monitor findings, while others reported reductions in prescribed medications under healthcare provider guidance.

Study Methodology

This 30-day open-label observational report summarizes the experiences of 40 participants, aged between 40 and 65, who used Electron Colloidal Magnesium. Participants provided feedback on their cardiovascular symptoms, daily well-being, sleep quality, and overall experiences throughout the observation period. Additional voluntary feedback was collected during a 90-day follow-up.